Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1195: BC-BET v2.0: Updates to an online Bladder Cancer Biomarker Evaluation tool

View through CrossRef
Abstract The Bladder Cancer Biomarker Evaluation Tool (BC-BET) is a web application for quickly evaluating candidate diagnostic and prognostic biomarkers in bladder cancer, based on publicly available gene expression datasets. Specifically, BC-BET evaluates whether a selected gene is differentially expressed between normal cells and tumor samples; between low- and high- grade tumors; and between non-muscle invasive and muscle-invasive tumors. BC-BET also evaluates whether a selected gene is significantly associated with survival, and whether the gene is associated with survival in two clinically important patient subsets: patients with low-grade, non-muscle invasive tumors; and patients with high-grade, muscle invasive tumors. Here we describe updates to BC-BET that include the inclusion of additional patient cohorts, and new features including multi-gene search, data visualization, additional data export options, and faster search times. BC-BET v2.0 contains gene expression data from 17 cohorts (N = 1846), and users can now query up to 500 genes at a time in order to quickly identify genes associated with bladder cancer. For single gene queries, dot plots can be generated for visualization of gene expression across groups; while Kaplan-Meier curves can be generated for survival analyses. BC-BET v2.0 also allows users to export the gene expression and clinical data, which would allow researchers to generate their own visualizations or to carry out additional analyses. Finally, the BC-BET backend was re-designed, resulting in more than a 2x fold increase in performance efficiency. We hope that this tool will continue to serve the bladder cancer research community and will ultimately lead to a better understanding of and treatment of this disease. The BC-BET web application as well as its source code is freely available from https://gdancik.github.io/BC-BET/. Citation Format: Garrett M. Dancik. BC-BET v2.0: Updates to an online Bladder Cancer Biomarker Evaluation tool [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1195.
American Association for Cancer Research (AACR)
Title: Abstract 1195: BC-BET v2.0: Updates to an online Bladder Cancer Biomarker Evaluation tool
Description:
Abstract The Bladder Cancer Biomarker Evaluation Tool (BC-BET) is a web application for quickly evaluating candidate diagnostic and prognostic biomarkers in bladder cancer, based on publicly available gene expression datasets.
Specifically, BC-BET evaluates whether a selected gene is differentially expressed between normal cells and tumor samples; between low- and high- grade tumors; and between non-muscle invasive and muscle-invasive tumors.
BC-BET also evaluates whether a selected gene is significantly associated with survival, and whether the gene is associated with survival in two clinically important patient subsets: patients with low-grade, non-muscle invasive tumors; and patients with high-grade, muscle invasive tumors.
Here we describe updates to BC-BET that include the inclusion of additional patient cohorts, and new features including multi-gene search, data visualization, additional data export options, and faster search times.
BC-BET v2.
0 contains gene expression data from 17 cohorts (N = 1846), and users can now query up to 500 genes at a time in order to quickly identify genes associated with bladder cancer.
For single gene queries, dot plots can be generated for visualization of gene expression across groups; while Kaplan-Meier curves can be generated for survival analyses.
BC-BET v2.
0 also allows users to export the gene expression and clinical data, which would allow researchers to generate their own visualizations or to carry out additional analyses.
Finally, the BC-BET backend was re-designed, resulting in more than a 2x fold increase in performance efficiency.
We hope that this tool will continue to serve the bladder cancer research community and will ultimately lead to a better understanding of and treatment of this disease.
The BC-BET web application as well as its source code is freely available from https://gdancik.
github.
io/BC-BET/.
Citation Format: Garrett M.
Dancik.
BC-BET v2.
0: Updates to an online Bladder Cancer Biomarker Evaluation tool [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.
Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1195.

Related Results

Purines modulate urinary bladder arteriolar tone
Purines modulate urinary bladder arteriolar tone
Bladder dysfunction affects millions of people, but few effective treatments are available. In humans, changes in bladder function correlate to changes in blood flow. In rodent mod...
Urinary bladder wall thickness in type 2 diabetes mellitus patients
Urinary bladder wall thickness in type 2 diabetes mellitus patients
Introduction: Diabetes mellitus is an increasing health challenge with accompanying urological complications. Over 50% of men and women with diabetes have bladder dysfunction. Acco...
Abstract 4948: Bladder cancer incidence: A systematic review and meta-analysis in SSA
Abstract 4948: Bladder cancer incidence: A systematic review and meta-analysis in SSA
Abstract Introduction: Bladder Cancer shows a substantial geographic disparity worldwide (1-3). The highest incidence rates are ...
Interview: Timothy Clinton
Interview: Timothy Clinton
What has driven you to specialise in urologic oncology, in particular the management of advanced testicular and bladder malignancies? My interest in urology started in medical scho...
Abstract 1115: BET bromodomain inhibition synergizes with MEK inhibitors in uveal melanoma
Abstract 1115: BET bromodomain inhibition synergizes with MEK inhibitors in uveal melanoma
Abstract Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Approximately 50% of the patients develop hepatic metastasis and the median...
Development of dual BET/HDAC inhibitors
Development of dual BET/HDAC inhibitors
Bezüglich der Arzneimittelforschung galt für sehr lange Zeit das Paradigma "ein Gen, ein Medikament, eine Krankheit". In jüngerer Zeit ändert sich dieses Paradigma jedoch auf Grund...
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Abstract The rapid growth of open access publishing (OAP) has significantly improved the accessibility and dissemination of scientific knowledge. However, this expansion has also c...

Back to Top